We are analyzing https://link.springer.com/article/10.1007/s10549-006-9242-8.

Title:
REporting recommendations for tumor MARKer prognostic studies (REMARK) | Breast Cancer Research and Treatment
Description:
Despite years of research and hundreds of reports on tumor markers in oncology, the number of markers that have emerged as clinically useful is pitifully small. Often initially reported studies of a marker show great promise, but subsequent studies on the same or related markers yield inconsistent conclusions or stand in direct contradiction to the promising results. It is imperative that we attempt to understand the reasons that multiple studies of the same marker lead to differing conclusions. A variety of methodologic problems have been cited to explain these discrepancies. Unfortunately, many tumor marker studies have not been reported in a rigorous fashion, and published articles often lack sufficient information to allow adequate assessment of the quality of the study or the generalizability of study results. The development of guidelines for the reporting of tumor marker studies was a major recommendation of the National Cancer Institute-European Organisation for Research and Treatment of Cancer (NCI-EORTC) First International Meeting on Cancer Diagnostics in 2000. As for the successful CONSORT initiative for randomized trials and for the STARD statement for diagnostic studies, we suggest guidelines to provide relevant information about the study design, pre-planned hypotheses, patient and specimen characteristics, assay methods, and statistical analysis methods. In addition, the guidelines suggest helpful presentations of data and important elements to include in discussions. The goal of these guidelines is to encourage transparent and complete reporting so that the relevant information will be available to others to help them to judge the usefulness of the data and understand the context in which the conclusions apply.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Social Networks

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't see how the site brings in money.

Many websites are intended to earn money, but some serve to share ideas or build connections. Websites exist for all kinds of purposes. This might be one of them. Link.springer.com has a secret sauce for making money, but we can't detect it yet.

Keywords {🔍}

cancer, google, scholar, pubmed, prognostic, article, cas, studies, tumor, altman, markers, breast, reporting, research, group, marker, sauerbrei, mcshane, statistics, taube, gion, clark, guidelines, national, factors, journal, recommendations, oncology, clinical, institute, ncieortc, diagnostics, clin, information, remark, data, statement, diagnostic, natl, inst, res, review, systematic, subcommittee, working, phd, nature, privacy, cookies, willi,

Topics {✒️}

month download article/chapter nci-eortc working group nci-eortc international meetings nature publishing group hayes df dana-farber cancer institute node-positive breast cancer node-negative breast cancer biological tumor markers full article pdf cancer diagnosis program author information authors angelo di leo privacy choices/manage cookies biometric research branch clinical practice guidelines translational research studies tumor marker studies cancer research uk enhanced prognostic system evaluate clinical utility national cancer institute national cancer institute] evidence-based practice nci-eortc tumor tissue retrieval willi sauerbrei ph predictive indicators tumor markers prognostic factor studies invasive breast carcinomas biomarkers prognostic markers cancer prognostic studies clinical cancer tests european economic area pre-planned hypotheses bast rc fenoglio-preiser cm moore dh ii vitro bromodeoxyuridine labeling archival tissue samples real-world performance bowel project experience thymidylate synthase expression reviewing submitted manuscripts randomised controlled trials financial support provided prognostic factors fail yale cancer center

Questions {❓}

Hilsenbeck SG, Clark GM, McGuire WL (1992) Why do so many prognostic factors fail to pan out?
Schilsky RL, Taube SE (2002) Introduction: Tumor markers as clinical cancer tests—are we there yet?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:REporting recommendations for tumor MARKer prognostic studies (REMARK)
         description:Despite years of research and hundreds of reports on tumor markers in oncology, the number of markers that have emerged as clinically useful is pitifully small. Often initially reported studies of a marker show great promise, but subsequent studies on the same or related markers yield inconsistent conclusions or stand in direct contradiction to the promising results. It is imperative that we attempt to understand the reasons that multiple studies of the same marker lead to differing conclusions. A variety of methodologic problems have been cited to explain these discrepancies. Unfortunately, many tumor marker studies have not been reported in a rigorous fashion, and published articles often lack sufficient information to allow adequate assessment of the quality of the study or the generalizability of study results. The development of guidelines for the reporting of tumor marker studies was a major recommendation of the National Cancer Institute-European Organisation for Research and Treatment of Cancer (NCI-EORTC) First International Meeting on Cancer Diagnostics in 2000. As for the successful CONSORT initiative for randomized trials and for the STARD statement for diagnostic studies, we suggest guidelines to provide relevant information about the study design, pre-planned hypotheses, patient and specimen characteristics, assay methods, and statistical analysis methods. In addition, the guidelines suggest helpful presentations of data and important elements to include in discussions. The goal of these guidelines is to encourage transparent and complete reporting so that the relevant information will be available to others to help them to judge the usefulness of the data and understand the context in which the conclusions apply.
         datePublished:2006-08-24T00:00:00Z
         dateModified:2006-08-24T00:00:00Z
         pageStart:229
         pageEnd:235
         sameAs:https://doi.org/10.1007/s10549-006-9242-8
         keywords:
            Tumor markers
            Guidelines
            NCI
            EORTC
            REMARK
            Prognostic
            Oncology
         image:
         isPartOf:
            name:Breast Cancer Research and Treatment
            issn:
               1573-7217
               0167-6806
            volumeNumber:100
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Kluwer Academic Publishers-Plenum Publishers
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Lisa M. McShane
               affiliation:
                     name:National Cancer Institute
                     address:
                        name:Biometric Research Branch, DCTD, National Cancer Institute, Bethesda, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Douglas G. Altman
               affiliation:
                     name:Wolfson College
                     address:
                        name:Cancer Research UK Medical Statistics Group, Cancer for Statistics in Medicine, Wolfson College, Oxford, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Willi Sauerbrei
               affiliation:
                     name:Universitaetsklinikum Freiburg
                     address:
                        name:Institut fuer Medizinische Biometrie und Medizinische Informatik, Universitaetsklinikum Freiburg, Freiburg, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Sheila E. Taube
               affiliation:
                     name:National Cancer Institute
                     address:
                        name:Cancer Diagnosis Program, National Cancer Institute, Bethesda, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Massimo Gion
               affiliation:
                     name:Ospedale Civile
                     address:
                        name:Centro Regionale Indicatori Biochimici di Tumore, Ospedale Civile, Venezia, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Gary M. Clark
               affiliation:
                     name:OSI Pharmaceuticals, Inc.
                     address:
                        name:OSI Pharmaceuticals, Inc., Boulder, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:REporting recommendations for tumor MARKer prognostic studies (REMARK)
      description:Despite years of research and hundreds of reports on tumor markers in oncology, the number of markers that have emerged as clinically useful is pitifully small. Often initially reported studies of a marker show great promise, but subsequent studies on the same or related markers yield inconsistent conclusions or stand in direct contradiction to the promising results. It is imperative that we attempt to understand the reasons that multiple studies of the same marker lead to differing conclusions. A variety of methodologic problems have been cited to explain these discrepancies. Unfortunately, many tumor marker studies have not been reported in a rigorous fashion, and published articles often lack sufficient information to allow adequate assessment of the quality of the study or the generalizability of study results. The development of guidelines for the reporting of tumor marker studies was a major recommendation of the National Cancer Institute-European Organisation for Research and Treatment of Cancer (NCI-EORTC) First International Meeting on Cancer Diagnostics in 2000. As for the successful CONSORT initiative for randomized trials and for the STARD statement for diagnostic studies, we suggest guidelines to provide relevant information about the study design, pre-planned hypotheses, patient and specimen characteristics, assay methods, and statistical analysis methods. In addition, the guidelines suggest helpful presentations of data and important elements to include in discussions. The goal of these guidelines is to encourage transparent and complete reporting so that the relevant information will be available to others to help them to judge the usefulness of the data and understand the context in which the conclusions apply.
      datePublished:2006-08-24T00:00:00Z
      dateModified:2006-08-24T00:00:00Z
      pageStart:229
      pageEnd:235
      sameAs:https://doi.org/10.1007/s10549-006-9242-8
      keywords:
         Tumor markers
         Guidelines
         NCI
         EORTC
         REMARK
         Prognostic
         Oncology
      image:
      isPartOf:
         name:Breast Cancer Research and Treatment
         issn:
            1573-7217
            0167-6806
         volumeNumber:100
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Kluwer Academic Publishers-Plenum Publishers
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Lisa M. McShane
            affiliation:
                  name:National Cancer Institute
                  address:
                     name:Biometric Research Branch, DCTD, National Cancer Institute, Bethesda, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Douglas G. Altman
            affiliation:
                  name:Wolfson College
                  address:
                     name:Cancer Research UK Medical Statistics Group, Cancer for Statistics in Medicine, Wolfson College, Oxford, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Willi Sauerbrei
            affiliation:
                  name:Universitaetsklinikum Freiburg
                  address:
                     name:Institut fuer Medizinische Biometrie und Medizinische Informatik, Universitaetsklinikum Freiburg, Freiburg, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Sheila E. Taube
            affiliation:
                  name:National Cancer Institute
                  address:
                     name:Cancer Diagnosis Program, National Cancer Institute, Bethesda, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Massimo Gion
            affiliation:
                  name:Ospedale Civile
                  address:
                     name:Centro Regionale Indicatori Biochimici di Tumore, Ospedale Civile, Venezia, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Gary M. Clark
            affiliation:
                  name:OSI Pharmaceuticals, Inc.
                  address:
                     name:OSI Pharmaceuticals, Inc., Boulder, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Breast Cancer Research and Treatment
      issn:
         1573-7217
         0167-6806
      volumeNumber:100
Organization:
      name:Kluwer Academic Publishers-Plenum Publishers
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:National Cancer Institute
      address:
         name:Biometric Research Branch, DCTD, National Cancer Institute, Bethesda, USA
         type:PostalAddress
      name:Wolfson College
      address:
         name:Cancer Research UK Medical Statistics Group, Cancer for Statistics in Medicine, Wolfson College, Oxford, UK
         type:PostalAddress
      name:Universitaetsklinikum Freiburg
      address:
         name:Institut fuer Medizinische Biometrie und Medizinische Informatik, Universitaetsklinikum Freiburg, Freiburg, Germany
         type:PostalAddress
      name:National Cancer Institute
      address:
         name:Cancer Diagnosis Program, National Cancer Institute, Bethesda, USA
         type:PostalAddress
      name:Ospedale Civile
      address:
         name:Centro Regionale Indicatori Biochimici di Tumore, Ospedale Civile, Venezia, Italy
         type:PostalAddress
      name:OSI Pharmaceuticals, Inc.
      address:
         name:OSI Pharmaceuticals, Inc., Boulder, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Lisa M. McShane
      affiliation:
            name:National Cancer Institute
            address:
               name:Biometric Research Branch, DCTD, National Cancer Institute, Bethesda, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Douglas G. Altman
      affiliation:
            name:Wolfson College
            address:
               name:Cancer Research UK Medical Statistics Group, Cancer for Statistics in Medicine, Wolfson College, Oxford, UK
               type:PostalAddress
            type:Organization
      name:Willi Sauerbrei
      affiliation:
            name:Universitaetsklinikum Freiburg
            address:
               name:Institut fuer Medizinische Biometrie und Medizinische Informatik, Universitaetsklinikum Freiburg, Freiburg, Germany
               type:PostalAddress
            type:Organization
      name:Sheila E. Taube
      affiliation:
            name:National Cancer Institute
            address:
               name:Cancer Diagnosis Program, National Cancer Institute, Bethesda, USA
               type:PostalAddress
            type:Organization
      name:Massimo Gion
      affiliation:
            name:Ospedale Civile
            address:
               name:Centro Regionale Indicatori Biochimici di Tumore, Ospedale Civile, Venezia, Italy
               type:PostalAddress
            type:Organization
      name:Gary M. Clark
      affiliation:
            name:OSI Pharmaceuticals, Inc.
            address:
               name:OSI Pharmaceuticals, Inc., Boulder, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Biometric Research Branch, DCTD, National Cancer Institute, Bethesda, USA
      name:Cancer Research UK Medical Statistics Group, Cancer for Statistics in Medicine, Wolfson College, Oxford, UK
      name:Institut fuer Medizinische Biometrie und Medizinische Informatik, Universitaetsklinikum Freiburg, Freiburg, Germany
      name:Cancer Diagnosis Program, National Cancer Institute, Bethesda, USA
      name:Centro Regionale Indicatori Biochimici di Tumore, Ospedale Civile, Venezia, Italy
      name:OSI Pharmaceuticals, Inc., Boulder, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(133)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.04s.

LINK . SPRINGER . COM {}